Skip to main content

Plegridy FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 3, 2021.

FDA Approved: Yes (First approved August 15, 2014)
Brand name: Plegridy
Generic name: peginterferon beta-1a
Dosage form: Injection
Company: Biogen Inc.
Treatment for: Multiple Sclerosis

Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Development timeline for Plegridy

Feb  1, 2021Approval Biogen Announces FDA Approval of Plegridy (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Aug 18, 2014Approval FDA Approves Plegridy (peginterferon beta-1a) for the Treatment of Multiple Sclerosis
Jul 19, 2013US and EU Regulatory Authorities Accept Plegridy (peginterferon beta-1a) Marketing Applications for Review
May 21, 2013Biogen Idec Submits Application to FDA for Approval of Plegridy (Peginterferon Beta-1a) in Multiple Sclerosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.